Investigational Drug Information for GLPG2737
✉ Email this page to a colleague
What is the drug development status for GLPG2737?
GLPG2737 is an investigational drug.
There have been 6 clinical trials for GLPG2737.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 29th 2017.
The most common disease conditions in clinical trials are Fibrosis, Cystic Fibrosis, and Arthrogryposis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are two US patents protecting this investigational drug and twenty international patents.
Summary for GLPG2737
| US Patents | 2 |
| International Patents | 20 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-11-29) |
| Vendors | 0 |
Recent Clinical Trials for GLPG2737
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Galapagos NV | Phase 2 |
| A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. | Galapagos NV | Phase 1 |
| GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | Galapagos NV | Phase 2 |
Clinical Trial Summary for GLPG2737
Top disease conditions for GLPG2737
Top clinical trial sponsors for GLPG2737
US Patents for GLPG2737
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG2737 | See Plans and Pricing | Compounds, compositions, and methods for modulating CFTR | Proteostasis Therapeutics, Inc. (Boston, MA) | See Plans and Pricing |
| GLPG2737 | See Plans and Pricing | Compounds, compositions, and methods for increasing CFTR activity | Proteostasis Therapeutics, Inc. (Boston, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG2737
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG2737 | Argentina | AR108203 | 2036-04-07 | See Plans and Pricing |
| GLPG2737 | Australia | AU2017248253 | 2036-04-07 | See Plans and Pricing |
| GLPG2737 | Brazil | BR112018070747 | 2036-04-07 | See Plans and Pricing |
| GLPG2737 | Canada | CA3019663 | 2036-04-07 | See Plans and Pricing |
| GLPG2737 | China | CN109563047 | 2036-04-07 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
